Unfair Competition: Restraint of Trade: Justification of Trade Boycotts under the Federal Antitrust Laws

1941 ◽  
Vol 29 (2) ◽  
pp. 258
Author(s):  
N. K. G.
1978 ◽  
Vol 6 (1) ◽  
pp. 15-25
Author(s):  
Terry Calvani

The attempt by the United States government to preserve competition and its benefits has produced a succession of legislation, popularly known as the antitrust laws, which began with the Sherman Antitrust Act of 1890. This law prohibits combinations in restraint of trade and monopolization of trade. The Federal Trade Commission Act of 1914 established a federal agency to enforce antitrust and outlawed “unfair” competition. The Clayton Act, passed in the same year and amended by the Robinson–Patman Act in 1936, forbids price discrimination, mergers, and other actions when judged destructive of competition.These statutes have generated an enormous quantity of litigation and have stimulated a plethora of literature. The following article, written by an expert who teaches and writes in the. field of antitrust, describes the more important works on the subject which, taken together, could constitute a basic collection of antitrust literature for law libraries inside and outside the United Slates.


1951 ◽  
Vol 13 (2) ◽  
pp. 229-243 ◽  
Author(s):  
Robert B. Dishman

The “rule of reason” remains after almost forty years the most curious obiter dictum ever indulged in by the Supreme Court of the United States. Mistaken though it was in its basic assumptions, the rule nevertheless persists as the Court's standard for construing the Sherman Act. This is not to say, as some critics have said, that the rule has seriously hampered the Department of Justice in enforcing the antitrust laws. We have it on the authority of Thurman Arnold that without the rule die Sherman Act would be “unworkable … because every combination between two men in business is in some measure a restraint of trade.” The rule, he has said, “has the effect of preventing the antitrust laws from destroying the efficiency of diose combinations that are actually serving, instead of exploiting, the consumer.” The fact remains, however, that in adopting the rule the Court erred in at least two respects: first, in applying a test of reasonableness where in the early cases at least none was called for and, second, in basing that rule on a misunderstanding of the common law. For the first of its sins the Court has been scolded many times; for the second, it has received surprisingly litde criticism.


1986 ◽  
Vol 11 (4) ◽  
pp. 465-500
Author(s):  
Abby Brown Wayne

AbstractIn Kartell v. Blue Shield of Massachusetts, Inc., the First Circuit held that Blue Shield's reimbursement practice known as the “ban on balance billing” did not constitute an unlawful restraint of trade in violation of the antitrust laws. Underlying the First Circuit's decision was deference to what it viewed as efforts by Blue Shield and by the Commonwealth to promote cost containment.This Comment argues that, to the contrary, under an appropriate analysis of antitrust law, the practices employed by Blue Shield did constitute unreasonable restraints of trade on the physicians' service industry in Massachusetts, given Blue Shield's market dominance in the Commonwealth. The Comment also argues that such inhibition of the competitive functioning of this industry is unwise, and that costs should instead be contained by effectuating the antitrust laws and encouraging the development of competitive forces within this industry.


2019 ◽  
Vol 8 (3) ◽  
pp. 15
Author(s):  
Michael M. Costello

Two national newspaper articles published in the Fall of 2018 addressed the issue of private health insurance provider contracts that act to exclude specific health systems from health plan networks.  Inevitably, the question arises: Are such agreements illegal restraints of trade actionable under federal and state antitrust laws? A long-standing tenet of antitrust law is that it exists to protect competition not competitors.  Excluding providers may be a legitimate outgrowth of the contracting process and therefore legal.  However, an examination of the contracting process may reveal anticompetitive intent to restrain trade.  The specific facts surrounding provider exclusion must be analyzed carefully in an effort to determine if there is illegal restraint of trade.


2004 ◽  
Vol 32 (1) ◽  
pp. 181-184
Author(s):  
Amy Garrigues

On September 15, 2003, the US. Court of Appeals for the Eleventh Circuit held that agreements between pharmaceutical and generic companies not to compete are not per se unlawful if these agreements do not expand the existing exclusionary right of a patent. The Valley DrugCo.v.Geneva Pharmaceuticals decision emphasizes that the nature of a patent gives the patent holder exclusive rights, and if an agreement merely confirms that exclusivity, then it is not per se unlawful. With this holding, the appeals court reversed the decision of the trial court, which held that agreements under which competitors are paid to stay out of the market are per se violations of the antitrust laws. An examination of the Valley Drugtrial and appeals court decisions sheds light on the two sides of an emerging legal debate concerning the validity of pay-not-to-compete agreements, and more broadly, on the appropriate balance between the seemingly competing interests of patent and antitrust laws.


Sign in / Sign up

Export Citation Format

Share Document